Takeda completes Shire acquisition
Takeda has completed its £46-billion acquisition of Shire, a deal that took just eight months to see through from announcement to close.
Read More
Tag: shire
Shire purchase backed by Takeda shareholders
Takeda shareholders have backed the firm’s proposed £46 billion acquisition of Shire.
Read More
Shire receives EU approval for Takhzyro
Shire has announced that the European Commission has approved its hereditary angioedema (HAE) drug Takhzyro.
Read More
Takeda gets European blessing for Shire acquisition
The European Commission has given its blessing for the proposed £46-billion acquisition of Shire by Takeda, paving the way for the deal’s completion.
Read More
FDA advisory committee backs Shire’s prucalopride
Shire’s prucalopride has taken a giant leap towards approval after winning the support of an FDA advisory committee for chronic idiopathic constipation.
Read More
Shire’s Veyvondi approved in Europe for bleeding disorder
European regulators have approved Shire’s von Willebrand Disease therapy Veyvondi.
Read More
Shire completes sale of oncology franchise to Servier
Shire has completed the sale of its oncology franchise to Servier in a deal valued at $2.4 billion.
Read More
Shire’s HAE drug Takhzyro gets green light in the US
Shire’s Takhzyro has been approved in the US for the prevention of attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Read More
Takeda gets US nod for Shire buy
Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire.
Read More
Shire bags paediatric label expansion for Cinryze in the US
US regulators have approved a label expansion for Shire’s Cinryze, allowing its use in children aged six and above with hereditary angioedema.
Read More
Takeda to buy Shire for £46 billion
Takeda is moving ahead with its quest to acquire UK-listed Shire, after the latter approved an offer equating to around £46 billion.
Read More
Shire, Takeda move closer to merger deal
Shire’s Board has notified Takeda that it would be “willing to recommend” the latter’s latest merger proposal to shareholders, which is now valued at £46 billion pounds.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
